Myriad Genetics’ Next-Generation Diagnostic Assays to Support Therapeutic Development & Precision Oncology
Wednesday, December 2, 2026 | 7 AM PT | 10 AM ET | 3 PM BT | 4PM CET
Join the Myriad Genetics' team for an exclusive webinar exploring how their novel next-generation diagnostic assays are supporting new therapeutic development and ultimately, enhancing the patient journey.
What Insights Will You Walk Away With?
Kirsten Timms, PhD, Senior Vice President, R&D, Myriad Genetics
The Detection of Homologous Recombination Deficiency (HRD) Using a Novel Prostate Cancer-Specific Genomic Instability Score (PrGIS)
- Learn about the development and diagnostic use of a new prostate genomic instability score (PrGIS)
- Understand how PrGIS is being used to support clinical studies for the development of next-generation therapeutics
Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics
The Clinical Validation of Myriad Genetics’ Ultra-Sensitive Pan-Cancer WGS-Based Precise MRD Assay
- Understand how ultra-sensitive, tumor-informed MRD testing is being applied across clinical and development settings
- Gain a clear view of where ultra-sensitive MRD testing delivers value today and how to apply it across your own programs
Who Can You Expect to Hear From?
Further Information on Myriad Genetics:
Myriad Genetics is a precision medicine company with deep expertise in companion diagnostics development and commercialization. Myriad Genetics partners with biopharmaceutical organizations across the full product lifecycle, offering biomarker discovery, assay development, clinical trial testing, regulatory strategy, and global CDx deployment. Leveraging validated platforms and extensive oncology experience, Myriad Genetics delivers robust, reproducible diagnostic solutions that align with targeted therapies. Their integrated laboratory infrastructure and regulatory capabilities enable streamlined approvals and scalable commercialization, supporting precision treatment strategies worldwide.